Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BCR::ABL1 status confers therapeutic sensitivity to Imatinib in patients with Acute Lymphoid Leukemia.
The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
This statement is based on a regulatory approval from the European Medicines Agency:
Glivec is indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.